Zynex, Inc. is a medical technology company specialized in the manufacturing and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring. The Companyâ€™s devices are intended for pain management to reduce reliance on medications and provide rehabilitation and increased mobility through the utilization of non-invasive muscle stimulation, electromyography technology, interferential current, neuromuscular electrical stimulation and transcutaneous electrical nerve stimulation. The Companyâ€™s products include Zynex Medical Products, which includes NexWave, NeuroMove, InWave, E-Wave, M-Wave; Private Labeled Supplies, which includes Electrodes and Batteries; Private Labeled Rehabilitation Products, which include Comfortrac/Saunders, JetStream/Pain Management Technologies, LSO Back Braces, Bracing (Knee and Wrist), and Dynacomp, and Zynex Monitoring Solutions Products, which includes CM-1500, CM-1600, NiCO CO-Oximeter, and HemeOx tHb Oximeter.

Employees

1,000

Sector

Advanced Medical Equipment & Technology

More about the company

Income Statement and Estimates

More financial data

Delayed OTC Markets Other stock markets 22:56:45 26/03/2026 +03			5-day change	1st Jan Change
0.0550 ^USD	+5.77%		-.--%	-56.35%

03-27	Altivera Medical Holdings, LLC acquired Zynex, Inc.	CI
03-27	Zynex, Inc. Secures Term Loan Credit Agreement Finalized	CI

Market Cap	3.83M 3.33M 3.11M 2.85M 5.38M 365M 5.47M 36.63M 14.35M 182M 14.38M 14.06M 600M	P/E 2023	40.3x	P/E 2024	89x
Enterprise Value	38.02M 33.04M 30.85M 28.32M 53.4M 3.62B 54.33M 364M 142M 1.81B 143M 140M 5.96B	EV / Sales 2023	2.17x	EV / Sales 2024	1.5x
Free-Float	38.37%	Yield 2023 *	-	Yield 2024	-

03-27	Altivera Medical Holdings, LLC acquired Zynex, Inc.	CI
03-27	Zynex, Inc. Secures Term Loan Credit Agreement Finalized	CI
03-26	Zynex, Inc. Emerged from Bankruptcy	CI
03-21	Court confirms Zynex plan of reorganization on March 19, 2026 - SEC filing	RE
03-19	Third Amended Reorganization Plan Approved for Zynex, Inc.	CI
02-20	Zynex Inc says SEC concluded investigation into Zynex, no enforcement action planned	RE
02-18	Zynex Inc resolves federal investigation into business practices	RE
02-10	Notice of Auction Cancellation and Designation of Successful Bidder Filed by Zynex, Inc.	CI
02-07	Third Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI
02-04	Zynex, Inc. Announces New In-Network Provider Status with Humana	CI
02-02	Second Amended Joint Disclosure Statement Conditionally Approved and Combined Hearing of Second Amended Disclosure Statement and Reorganization Plan Approved for Zynex, Inc.	CI
02-01	Second Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI
01-29	First Amended Combined Joint Reorganization Plan and Disclosure Statement Filed by Zynex, Inc.	CI

01/08/25	RBC Capital Adjusts Price Target on Zynex to $2 From $3, Maintains Sector Perform Rating	MT
01/08/25	HC Wainwright Downgrades Zynex to Neutral From Buy	MT
31/07/25	Medtech Zynex's Q2 revenue falls more than expected, names new CEO, suspends forecast	RE
15/07/25	RBC Cuts Price Target on Zynex to $3 From $4, Keeps Sector Perform Rating	MT
30/04/25	RBC Cuts Price Target on Zynex to $4 From $5, Keeps Sector Perform Rating	MT

Zynex, Inc. Stock

Stocks

ZYXI

US98986M1036

Advanced Medical Equipment & Technology

Valuation: Zynex, Inc.

Chart: Zynex, Inc.

Latest news : Zynex, Inc.

Last Transcript: Zynex, Inc.

Analysts' recommendations: Zynex, Inc.

Press Releases: Zynex, Inc.

News in other languages: Zynex, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Zynex, Inc.

Latest insider transactions

Other Advanced Medical Equipment & Technology

Financials

Company Profile

Income Statement and Estimates

03-27	ZYXIQ Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026	NE
03-26	ZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements	PR
03-26	ZYXIQ SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Zynex (ZYXIQ) Investors of Securities Class Action Deadline on April 21, 2026	NE
03-25	Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Zynex, Inc. Lawsuit - ZYXIQ	PR
03-24	ZYXI SHAREHOLDER UPDATE: Hagens Berman Alerts Zynex (ZYXI / ZYXIQ) Investors to Securities Class Action Following Bankruptcy and Federal Fraud Settlements	PR

27/12/22	Top 50 Small-caps 2023
21/12/22	Top 50 Small-caps 2023
21/10/21	Los valores del Nasdaq con mayor crecimiento
21/10/21	Les actions du Nasdaq avec la plus forte croissance

Current year	0.02	0.13
1 year	0.02	2.1
3 years	0.02	13.77
5 years	0.02	17.25
10 years	0.02	27.02

Manager	Title	Age	Since
Steven Dyson CEO	Chief Executive Officer	53	18/08/2025
Vikram Bajaj DFI	Director of Finance/CFO	50	18/08/2025
John Bibb LAW	General Counsel	53	18/08/2025

Director	Title	Age	Since
Vikram Bajaj BRD	Director/Board Member	50	26/03/2026
John Bibb BRD	Director/Board Member	53	26/03/2026

Date	Insider	Type	Main position	Quantity	% Market Cap.
7/27/25 A	Anna Lucsok	Free	Chief Operating Officer	11,293	0.0355%
6/5/25 A	Daniel Moorhead	Tax	Chief Financial Officer	8,982	0.0282%
5/15/25 A	Barry Michaels	Free	Director	10,000	0.0314%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ZYNEX, INC.	+5.77%	-.--%	-95.65%	-99.34%	1.69M
THERMO FISHER SCIENTIFIC, INC.	+0.14%	+2.47%	+22.89%	+4.56%	212B
DANAHER CORPORATION	+1.38%	+0.04%	-0.44%	-23.64%	137B
INTUITIVE SURGICAL, INC.	+5.44%	+4.57%	-22.80%	+19.87%	125B
BOSTON SCIENTIFIC CORPORATION	+2.19%	+4.77%	-55.35%	-6.29%	69.46B
EDWARDS LIFESCIENCES CORPORATION	+2.79%	+6.17%	+10.08%	+10.20%	49.56B
SIEMENS HEALTHINEERS AG	+6.10%	+9.98%	-15.42%	-19.36%	47.2B
AGILENT TECHNOLOGIES, INC.	+0.47%	+0.71%	+20.92%	+11.05%	39.08B
WATERS CORPORATION	-0.72%	+1.20%	+31.54%	+28.91%	37.05B
ILLUMINA, INC.	-1.61%	+6.81%	+105.58%	+9.19%	30.97B
Average	+2.09%	+0.57%	+0.13%	-6.49%	74.75B
Weighted average by Cap.	+1.79%	+2.80%	+4.19%	+1.54%

	2023	2024
Net sales	184M 160M 150M 137M 259M 17.57B 263M 1.76B 691M 8.76B 692M 677M 28.9B	192M 167M 156M 143M 270M 18.33B 275M 1.84B 721M 9.14B 723M 707M 30.16B
Net income	9.73M 8.46M 7.9M 7.25M 13.67M 928M 13.91M 93.11M 36.47M 463M 36.56M 35.75M 1.53B	2.99M 2.6M 2.43M 2.23M 4.21M 285M 4.28M 28.65M 11.22M 142M 11.25M 11M 469M
Net Debt	31.59M 27.45M 25.63M 23.53M 44.37M 3.01B 45.14M 302M 118M 1.5B 119M 116M 4.95B	34.19M 29.72M 27.74M 25.47M 48.02M 3.26B 48.86M 327M 128M 1.63B 128M 126M 5.36B